Bolt Biotherapeutics, Inc. (BOLT) vs IMMURON (IMRN)
- Bolt Biotherapeutics, Inc. BOLT 4.06 −4.25%
- IMMURON IMRN 0.98 −4.85%
Bolt Biotherapeutics, Inc. and IMMURON are both Biotechnology companies. Bolt Biotherapeutics, Inc. and IMMURON are of similar size ($8.3M and $8.2M). Bolt Biotherapeutics, Inc. grew revenue faster over the last twelve months: 12.8% against −6.62%. IMMURON has the higher net margin (−262.7% vs −611.5%) and the higher return on invested capital (0.00% vs −143.8%). Across the 16 metrics below, IMMURON leads on 12 and Bolt Biotherapeutics, Inc. on 4.
Valuation
Profitability
| Metric | BOLT | IMRN | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 71.28% | 65.16% |
| Operating margin | (654.53%) | 0.00% | 0.00% |
| Net margin | (611.47%) | (262.71%) | 0.00% |
| Free cash flow margin | (655.72%) | 0.00% | 0.00% |
| Return on equity | (111.65%) | 0.00% | (56.36%) |
| Return on assets | (49.62%) | 0.00% | (48.04%) |
| Return on invested capital | (143.75%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack